Government of Canada and FCM Invest $16.9 million to Grow Greener Communities and Enhance Wellbeing with Tree Planting Projects Français
Today, the Honourable Tim Hodgson, Minister of Energy and Natural Resources, and Rebecca Bligh, President of the Federation of Canadian Municipalities (FCM), announced an investment of $16,886,020 to support communities in planting 77,000 new trees.
The 27 projects receiving funding will result in 77,519 new trees planted in Prince Edward Island, Nova Scotia, New Brunswick, Ontario, Manitoba, Saskatchewan, Alberta and British Columbia, restoring or increasing canopy in rural and urban areas, enhancing recreational spaces, improving habitat connectivity, providing health benefits to residents and creating tree maintenance jobs.
The funded projects will plant trees on streets and boulevards, in parks and recreational spaces, on private and institutional land, in residential areas and for ecological restoration and connectivity. Notable projects include:
The City of Kitchener, ON, will plant 19,207 trees to enhance park spaces, expand naturalized areas and create habitat for wildlife and pollinators, while replacing trees that were lost to Emerald Ash Borer infestations. The project focuses on planting trees in areas with low canopy cover to reduce heat island effects and to ensure an equitable distribution of environmental benefits to all community members. The innovative tool the City developed to help prioritize tree planting in underserved areas was recognized with a Smart 20 Award from Smart Cities Connect.
Assiniboine Park Conservancy, a not-for-profit organization working in partnership with City of Winnipeg, MB, will plant 600 trees in Assiniboine Park. The initiative aims to enrich the biodiversity, forest health and ecosystem services of the area, while addressing the loss of trees due to Dutch Elm disease and helping achieve 42% canopy coverage by 2065.
The City of Charlottetown, PEI, in partnership with local watershed groups, will plant 1,200 trees and shrubs in 4 parks across the city. In the aftermath of Hurricane Fiona in 2022, the city lost an estimated 12,600 mature trees, dropping the canopy cover rate from 20.9% to 17.6%. The project is a key part of the city's efforts to restore canopy cover levels by 2034.
The City of Ottawa, ON, working in partnership with EnviroCentre, a not-for-profit organization, will plant 3,750 trees on private residential lands. As approximately 40% of Ottawa's urban area is private property, planting on residential lands is an important opportunity to expand canopy cover and provide benefits to residents, like cleaning the air and reducing the impact of heat waves.
Funding for these projects is being provided by the Government of Canada's 2 Billion Trees Program and delivered through FCM's Growing Canada's Community Canopies (GCCC) initiative. Announced in May 2024, GCCC will support the planting of at least 1.2 million new trees across Canada by the end of March 2031 while offering funding, resources and coaching to communities. Communities looking to expand their tree canopies can apply for funding until September 18, 2025. Tree planting funding will accept applications until September 18, 2025, for the 2026 planting season to support communities in expanding their canopies.
For more information about funded projects, please see the backgrounder.
"Trees are a powerful tool in building stronger, more-resilient communities. This project is a great example of local leadership driving national progress which will deliver meaningful benefits for Canadians and our environment. Through the 2 Billion Trees program, we are proud to partner with the Federation of Canadian Municipalities to grow greener, healthier and more-resilient neighbourhoods across the country for generations to come."
— The Honourable Tim Hodgson, Minister of Energy and Natural Resources
"This government is committed to protecting and restoring nature like never before. Planting trees is one of the most effective ways to fight climate change, improve air and water quality, protect biodiversity, create good jobs, and bring nature closer to Canadians. The thousands of trees being planted in communities across the country will provide health and ecological benefits for generations to come."
— The Honourable Julie Dabrusin, Minister of Environment and Climate Change
"Trees are an essential part of the fabric of our communities, and the projects funded through GMF's Growing Canada's Community Canopies initiative will build greener and healthier spaces for all Canadians. Restoring and expanding tree canopies in communities through new tree planting efforts will protect and restore vital ecosystems and create local jobs while providing tangible health benefits to residents. Investing in our canopies today is an investment in the quality of life for generations to come."
— Rebecca Bligh, FCM President
About FCM's Green Municipal Fund
FCM's Green Municipal Fund (GMF) is a globally unique organization providing funding and education to municipalities to help them both reach net-zero and build resilient communities, while also delivering economic and social benefits such as jobs, housing and infrastructure. Since inception in 2000, it has helped reduce greenhouse gas emissions by 2.9 million tonnes, funded more than 13,000 person-years of employment, enabled nearly 30,000 sustainable affordable housing units, and contributed $1.24 billion to the national GDP via the more than 2,336 approved projects. GMF manages approximately $2.4 billion in programs funded by the Government of Canada.
Quick facts
GMF's Growing Canada's Community Canopies (GCCC) is a $291M initiative, ending in 2031, that supports planting new trees across the country. GCCC funds planting the right type of trees in the right places so that communities across Canada can grow, manage and protect their tree canopies. The initiative is designed with smaller, rural, and remote communities in mind to encourage local climate action while enhancing tree survivability rates, fostering equitable access to trees across communities.
Trees offer vital ecosystem services to communities as they provide carbon sequestration, stormwater management, cooling and air filtration. For example, the annual value of ecosystem services by the Niagara Peninsula in Ontario is estimated at $331 million.
Investing in green infrastructure delivers substantial returns. According to TD Economics, for every dollar spent on annual maintenance, Toronto's urban forest returns anywhere from $1.35 – $3.20 worth of benefits and cost savings each year. TD Economics (2014, June 9).
Trees improve public health by reducing stress and air pollution. For example, PaRX is a nature prescription program that emphasizes nature as a tool for improving mental and physical health.
Through a partnership with Tree Canada, urban forestry experts provide personalized support to tree planting funding applicants in the application and implementation phases of projects, bridging the urban forestry knowledge gap many communities face. The guidance from urban forestry coaches helps ensure high tree survivability rates and maximize the environmental and social impacts of planting projects.
GCCC has produced an evolving suite of knowledge and training resources designed to enhance urban forestry expertise in Canadian communities. Resources cover topics from selecting the right species and planting site to putting equity at the centre of tree planting projects.
Associated links
Federation of Canadian Municipalities
Green Municipal Fund
Growing Canada's Community Canopies
GCCC Tree planting funding
GCCC Urban forestry coaching
Government of Canada 2 Billion Trees Commitment
Government of Canada 2030 Emissions Reduction Plan
Tree Canada
SOURCE Federation of Canadian Municipalities (FCM)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
25 minutes ago
- Cision Canada
British Columbia Joins Other Provincial Public Drug Plans Now Reimbursing FOQUEST® on their Formulary for Attention Deficit Hyperactivity Disorder (ADHD)
TORONTO, July 23, 2025 /CNW/ - Elvium Life Sciences is pleased to announce the addition of FOQUEST ® (methylphenidate hydrochloride controlled release capsules) to the British Columbia 1 PharmaCare formulary and First Nations Health Authority (FNHA) Pharmacy Benefit. With provincial funding in place in British Columbia, FOQUEST ® is now reimbursed from coast to coast on all provincial drug plans across Canada. "Public funding in British Columbia ensures equitable access to ADHD treatments in BC," said Juanita Beaudry, Executive Director of the Centre for ADHD Awareness (CADDAC) "This latest approval now provides access across Canada to another treatment option for patients." British Columbia now joins Alberta 2, Saskatchewan 3, Manitoba 4, Ontario 5, Quebec 6, Atlantic Canada 7,8,9,10, the Non-Insured Health Benefit Plan 11 and Correctional Service Canada in providing public formulary coverage for FOQUEST ® for the treatment of ADHD in patients aged six years and older. "Elvium Life Sciences is very pleased that British Columbia has now included Foquest on the BC PharmaCare Formulary to give physicians an additional choice for their ADHD patients who require public coverage," said Jodan Ratz, Country Medical Director at Elvium Life Sciences. "We thank the province for its decision which now means that all ADHD patients aged six years of age and older have equivalent access to Foquest should this be the right treatment for them." See the full Canadian Product Monograph for FOQUEST ® 12 The Product Monograph for FOQUEST ® contains a Serious Warning and Precaution for drug dependence, emphasizing that abuse of FOQUEST ® can lead to dependence. Healthcare professionals should assess the risk of abuse prior to prescribing FOQUEST ®, including in patients with a history of drug dependence or alcoholism, and monitor for signs of abuse and dependence while patients are on therapy. FOQUEST ® is a once-daily, long-acting methylphenidate controlled-release capsule for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients greater than or equal to six years of age. The maximum daily dose of FOQUEST ® for children and adolescents (6 to <18 years old) is 70mg, and the maximum daily dose for adults (≥18 years old) is 100 mg. Adverse events observed with FOQUEST ® treatment mainly reflect side effects commonly associated with methylphenidate use. Very common adverse events reported by patients treated with FOQUEST ® were headache, insomnia, decreased appetite and abdominal pain. Most of the events were mild to moderate in severity. About Elvium Life Sciences Elvium Life Sciences is an independent associated company of Purdue Pharma (Canada), that focuses on specialty pharmaceutical products committed to providing treatment options for patients who suffer from the symptoms of Attention Deficit/Hyperactivity Disorder (ADHD) and products for ophthalmology. For more information, please visit
Cision Canada
an hour ago
- Cision Canada
Canada advances initiatives to protect the right to a healthy environment and enhance chemicals management Français
GATINEAU, QC, July 23, 2025 /CNW/ - To protect human health and the environment for future generations, the federal government is taking decisive action. Recognizing the deep interconnection between Canadian health and the environment, these sustainable efforts will create a clean and safe environment for all. The Government of Canada is now releasing: the Implementation Framework for the Right to a Healthy Environment under the Canadian Environmental Protection Act, 1999 (CEPA) the Plan of Priorities for chemicals management the Strategy to Replace, Reduce or Refine Vertebrate Animal Testing under CEPA These publications are key requirements under the modernized Canadian Environmental Protection Act, 1999 (CEPA). The Implementation Framework sets out the meaning of the right to a healthy environment and provides guidance on how the Government of Canada considers this right in the administration of CEPA. The Framework provides a new lens for decision-making to support and encourage strong protection of both the environment and people who may be disproportionally impacted by pollution, now and in the future. The Plan of Priorities outlines upcoming initiatives to address chemical substances in Canada. It includes a list of substances to be assessed and elaborates on activities that support the assessment, control, and management of risks posed by substances. This Plan builds on Canada's existing strong foundation for chemicals management. Linked to the Plan of Priorities, the Strategy to Replace, Reduce or Refine Vertebrate Animal Testing will help guide continued efforts toward the replacement, reduction, or refinement of vertebrate animal testing under CEPA. These initiatives work together to help protect the environment and the health of all people in Canada. Quotes "The Implementation Framework for the Right to a Healthy Environment under CEPA and the Plan of Priorities represent important steps forward in safeguarding the health of people in Canada and the environment. Initiatives like these will allow us to respond effectively to a changing and complex global chemical landscape and ensure that the right to a healthy environment is considered when making decisions under CEPA." – The Honourable Julie Dabrusin, Minister of Environment and Climate Change Quick facts The Canadian Environmental Protection Act, 1999 is one of Canada's core environmental laws. On June 13, 2023, Bill S-5, Strengthening Environmental Protection for a Healthier Canada Act, received Royal Assent. This was the first set of comprehensive amendments in over 25 years to the Canadian Environmental Protection Act, 1999. A right to a healthy environment in the CEPA context is recognized in the preamble of the modernized Canadian Environmental Protection Act, 1999. Canada's Chemicals Management Plan is enabled by the Canadian Environmental Protection Act, 1999. This Plan helps protect human health and the environment by assessing and managing the risks posed from a wide range of substances. More than 200 risk-management instruments are already in place to manage the risks from substances determined to be harmful under the Canadian Environmental Protection Act, 1999. Contacts Keean Nembhard Press Secretary Office of the Minister of Environment and Climate Change 343-552-2387 [email protected] Media Relations Environment and Climate Change Canada 819-938-3338 or 1-844-836-7799 (toll-free) [email protected] Environment and Climate Change Canada's X page Environment and Climate Change Canada's Facebook page Environment and Natural Resources in Canada's Facebook page Environment and Climate Change Canada's LinkedIn page Environment and Climate Change Canada's Instagram page SOURCE Environment and Climate Change Canada
Cision Canada
6 hours ago
- Cision Canada
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
VANCOUVER, BC, July 23, 2025 /CNW/ -- USA News Group News Commentary – Cancer diagnoses are climbing fastest among younger women, sparking alarm that looming cuts to U.S. research budgets could stall progress in prevention and treatment. Adding to the strain, federal and state regulators are re‑examining mRNA vaccines, creating a cloud of uncertainty over future cancer‑funding priorities. Yet even amid this policy turbulence, a new wave of oncology innovators is lining up near‑term milestones that could reshape the landscape—led by Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Cue Biopharma, Inc. (NASDAQ: CUE), Verastem, Inc. (NASDAQ: VSTM), Allogene Therapeutics, Inc. (NASDAQ: ALLO), and Perspective Therapeutics, Inc. (NYSE-American: CATX). While regulatory red tape tightens, surging diagnoses of colorectal and other GI cancers in young people demand quicker innovation in oncology. Forecasts suggest worldwide cancer‑drug revenues could blow past US$900 billion by 2034. Within that, next‑gen therapies built on precision techniques are slated to reach US$175.2 billion, advancing at a brisk 7.35% annual clip. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) recently held a well‑attended key opinion leader (KOL) webinar where pancreatic and gastrointestinal cancer specialists dissected pelareorep's clinical history, its biomarker data package, and where the oncolytic virus could slot into evolving chemotherapy and immunotherapy regimens. "I want to thank our esteemed panel of oncologists for their meaningful contributions to our KOL event," said Jared Kelly, CEO of Oncolytics. "Their insights underscore a critical and timely message: pelareorep is a compelling immunotherapy platform that is well situated for combination strategies and a highly differentiated asset for pharma partners looking to expand or establish leadership in GI oncology. We are committed to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers." The panel revisited survival gains in metastatic pancreatic ductal adenocarcinoma (mPDAC), reviewed translational evidence of "cold‑to‑hot" tumor conversion, and outlined next steps for a registration-enabling study. Management said feedback from the discussion would inform both upcoming trial designs and partnering talks now underway. The event came on the heels of Oncolytics having rolled out an expanded translational‑data review that tightened the scientific case for pelareorep, an intravenously delivered oncolytic reovirus. Renewed analyses from the GOBLET gastrointestinal cancer study and the AWARE‑1 breast cancer study confirmed that the virus replicates inside tumors, switches on interferon signaling in the immune system, and draws tumor‑infiltrating lymphocytes into the tumor microenvironment. "This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action," said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. "We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME – all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep." Investigators also recorded higher PD‑L1 expression and tracked newly expanded cytotoxic T‑cell clones in blood samples that matched those inside shrinking lesions—molecular fingerprints that point to stronger responses when pelareorep is combined with standard-of-care treatments and checkpoint inhibitors. "The collection of data here show that pelareorep works how a cancer immunotherapy should work," said Jared Kelly, CEO of Oncolytics. "Pelareorep is a versatile product candidate with strong platform potential to enhance immunological responses in multiple indications, including hard-to-treat cancers. Such compelling findings should be exciting to strategic partners focused on finding a platform immunotherapy in large indications with high unmet medical needs." Clinical outcomes already hint at real‑world benefit. In more than 100 first‑line mPDAC patients, pelareorep‑based regimens achieved a 21.9% two‑year overall‑survival rate versus a 9.2% historical benchmark. A separate single‑arm study that paired pelareorep with chemotherapy and a checkpoint blocker produced a 62% objective‑response rate—especially notable given that no checkpoint therapy is approved in this cancer today. In hormone‑receptor‑positive, HER2‑negative metastatic breast cancer (HR+/HER2‑ mBC), two randomized trials added more than ten months of median overall survival, while BRACELET‑1 nearly doubled median progression‑free survival to 12.1 months compared with 6.4 months for control patients. To steer these data toward value‑creating deals and late‑stage trials, the company strengthened its leadership earlier this year by appointing industry veteran Jared Kelly as CEO and naming Andrew Aromando Chief Business Officer. The duo previously helped guide Ambrx Biopharma into a US$2 billion sale to Johnson & Johnson, experience the board believes will support capital‑efficient development and strategic partnering for pelareorep. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications," said Kelly. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy." As CBO, Aromando is now leading global business development and helping shape the company's corporate, clinical, and regulatory strategies. The leadership tandem is expected to prioritize partnering and expansion opportunities while preserving capital efficiency—a strategy well-suited for pelareorep's growing clinical profile. "I'm thrilled to join Oncolytics at such a pivotal moment in its evolution," said Aromando. "With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term." Pelareorep currently holds FDA Fast Track designations in mPDAC (pancreatic cancer) and HR+/HER2‑ mBC (breast cancer), along with Orphan‑Drug status for pancreatic cancer in the United States and Europe. With mechanistic proof, survival data that outperform historical controls, and fresh validation from the recent KOL event, Oncolytics Biotech is aligning its clinical, regulatory, and business strategies to move pelareorep into registration‑enabling trials and position it as a backbone immunotherapy across solid tumors. In other recent industry developments and happenings in the market include: Cue Biopharma, Inc. (NASDAQ: CUE) recently reported that adding CUE‑101 to pembrolizumab produced a 50% overall response rate in patients with recurrent/metastatic HPV‑positive head and neck cancer who had a combined positive score (CPS) ≥ 1, including the same 50% response in those with low CPS 1–19. The regimen has now generated two complete responses, an 88% 12‑month overall survival rate, and a median overall survival of 32 months, handily outperforming historical pembrolizumab data. "The culmination of maturing data further support our conviction that CUE-101, representative of our approach with the CUE-100 series, demonstrates a potential breakthrough therapeutic approach for establishing a new standard of care," said Dan Passeri, CEO of Cue Biopharma. "With this maturing data, we are further emboldened in our conviction that our Immuno-STAT ® platform represents transformative potential for selectively modulating the patient's immune system." Verastem, Inc. (NASDAQ: VSTM) recently published Phase 2 RAMP 201 results in the Journal of Clinical Oncology, showing avutometinib + defactinib delivered a 31% confirmed overall response rate in recurrent low‑grade serous ovarian cancer, rising to 44% in KRAS‑mutant tumors. "The publication of the primary analysis of the RAMP 201 study in recurrent low-grade serous ovarian cancer in the Journal of Clinical Oncology reflects the meaningful clinical advancement demonstrated by the combination of avutometinib plus defactinib for patients with recurrent low-grade serous ovarian cancer," said John Hayslip, M.D., Chief Medical Officer at Verastem Oncology. "The findings supported the recent FDA approval of the combination in KRAS-mutated recurrent low-grade serous ovarian cancer and our ongoing global Phase 3 RAMP 301 trial of the combination in recurrent low-grade serous ovarian cancer with and without a KRAS mutation." Median progression‑free survival reached 12.9 months overall and 31.0 months in the KRAS‑mutant subgroup, with 82% of patients experiencing some tumor shrinkage regardless of mutation status. Back in June, Allogene Therapeutics, Inc. (NASDAQ: ALLO) presented updated Phase 1 TRAVERSE data showing a single dose of ALLO‑316 achieved a 31% confirmed response rate in heavily pre‑treated renal cell carcinoma patients whose tumors expressed CD70 in ≥ 50 % of cells. "ALLO-316 is showing clear evidence of targeted antitumor activity in patients who had failed most or all approved therapies for advanced or metastatic renal cell carcinoma," said Zachary Roberts, M.D., Ph.D., EVP, Research and Development and Chief Medical Officer at Allogene. "Our proprietary Dagger technology allows the use of a standard cyclophosphamide and fludarabine-based lymphodepletion regimen with a single dose of ALLO-316. Strong CAR T-cell kinetics and extensive infiltration of tumor tissue by CAR T cells are combining to generate deep and durable remissions. These are results that were previously considered out of reach for patients with advanced solid tumors." Four of five responders remain in remission—including one lasting more than 12 months—while safety remained manageable with no graft‑versus‑host disease observed. Investigators say the results highlight allogeneic CAR T's potential in solid tumors and justify continued expansion of the study. Perspective Therapeutics, Inc. (NYSE-American: CATX) recently began recruiting the third dose‑escalation cohort of its Phase 1/2a trial testing [²¹²Pb]VMT‑α‑NET in unresectable or metastatic somatostatin receptor 2 (SSTR2)‑positive neuroendocrine tumors, raising the fixed dose by 20% to 6 mCi. Earlier cohorts showed anti‑tumor activity with mostly low‑grade adverse events, prompting FDA alignment to explore whether the higher dose can further enhance efficacy. "We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile." The company plans additional safety and efficacy readouts, including dosimetry analyses, at scientific meetings in 2H 2025. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
